Summit Financial LLC Boosts Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Summit Financial LLC increased its holdings in Thermo Fisher Scientific by 11.7% to a total of 5,767 shares, now worth approximately $2.87 million.
• Despite several upgrades in stock ratings, including a target price increase from UBS Group to $500, Thermo Fisher's stock recently declined by 2.3% to around $483.43.
• Thermo Fisher Scientific declared a quarterly dividend of $0.43, representing an annualized yield of 0.4%, with the payment date set for October 15th.

Summit Financial LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,767 shares of the medical research company's stock after acquiring an additional 606 shares during the quarter. Summit Financial LLC's holdings in Thermo Fisher Scientific were worth $2,870,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Revolve Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the period. Port Capital LLC boosted its position in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after acquiring an additional 22 shares during the last quarter. Clark Capital Management Group Inc. boosted its position in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after acquiring an additional 23 shares during the last quarter. Monograph Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 0.3% in the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after buying an additional 23 shares during the last quarter. Finally, Intergy Private Wealth LLC lifted its position in Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after buying an additional 23 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMO. UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Stock Down 2.3%

Thermo Fisher Scientific stock opened at $483.4280 on Friday. The stock has a market capitalization of $182.55 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.64 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The business has a 50 day simple moving average of $441.06 and a 200-day simple moving average of $458.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 295 shares of the business's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $500.04, for a total transaction of $147,511.80. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,591,606.96. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,896 shares of company stock worth $8,593,838 over the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.